Alkermes
ALKS
#3159
Rank
ยฃ3.50 B
Marketcap
ยฃ21.25
Share price
2.30%
Change (1 day)
-11.37%
Change (1 year)

P/E ratio for Alkermes (ALKS)

P/E ratio as of December 2025 (TTM): 13.8

According to Alkermes's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 13.7585. At the end of 2024 the company had a P/E ratio of 12.9.

P/E ratio history for Alkermes from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202412.9-0.04%
202312.9-147.4%
2022-27.2-64.89%
2021-77.5172.37%
2020-28.575.82%
2019-16.2
2017-53.130.98%
2016-40.6-22.32%
2015-52.2-82.16%
2014-293

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Acorda Therapeutics
ACOR
-0.0676-100.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
18.3 33.26%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
19.9 44.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
14.8 7.39%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
30.2 119.41%๐Ÿ‡ฌ๐Ÿ‡ง UK
Teva Pharmaceutical Industries
TEVA
48.3 251.15%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Zogenix
ZGNX
-6.56-147.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
13.0-5.17%๐Ÿ‡ซ๐Ÿ‡ท France
Novartis
NVS
18.6 35.21%๐Ÿ‡จ๐Ÿ‡ญ Switzerland

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.